These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 20703230

  • 1. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
    Ohishi M, Takeya Y, Tatara Y, Yamamoto K, Onishi M, Maekawa Y, Kamide K, Rakugi H.
    Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
    [Abstract] [Full Text] [Related]

  • 2. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL, Ekhlas A, Nguyen JM, Moranne O.
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [Abstract] [Full Text] [Related]

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 4. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

  • 5. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
    Bomback AS, Rekhtman Y, Klemmer PJ, Canetta PA, Radhakrishnan J, Appel GB.
    J Am Soc Hypertens; 2012 Jul; 6(5):338-45. PubMed ID: 22995802
    [Abstract] [Full Text] [Related]

  • 6. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.
    Segura J, Praga M, Campo C, Rodicio JL, Ruilope LM.
    J Renin Angiotensin Aldosterone Syst; 2003 Mar; 4(1):43-7. PubMed ID: 12692753
    [Abstract] [Full Text] [Related]

  • 7. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 8. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 9. Renal protective effect in hypertensive patients: the high doses of angiotensin II receptor blocker (HARB) study.
    Ohishi M, Takagi T, Ito N, Tatara Y, Hayashi N, Shiota A, Iwamoto Y, Katsuya T, Rakugi H, Ogihara T.
    Hypertens Res; 2007 Dec 21; 30(12):1187-92. PubMed ID: 18344623
    [Abstract] [Full Text] [Related]

  • 10. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
    Trimarchi H, Muryan A, Young P, Forrester M, Iotti A, Pereyra H, Lombi F, Seminario O, Alonso M, Iotti R.
    Medicina (B Aires); 2007 Dec 21; 67(5):445-50. PubMed ID: 18051227
    [Abstract] [Full Text] [Related]

  • 11. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.
    J Hypertens; 2000 Jan 21; 18(1):89-95. PubMed ID: 10678548
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 21; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 13. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A, Divchev D, Luchtefeld M, Schieffer B.
    Minerva Cardioangiol; 2009 Dec 21; 57(6):773-85. PubMed ID: 19942847
    [Abstract] [Full Text] [Related]

  • 14. Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing.
    Hermida RC, Ayala DE, Fontao MJ, Mojón A, Fernández JR.
    Chronobiol Int; 2010 Jul 21; 27(6):1287-303. PubMed ID: 20653455
    [Abstract] [Full Text] [Related]

  • 15. Is the reno-protective effect of valsartan dose dependent? A comparative study of 80 and 160 mg day(-1).
    Saikawa T, Sasaki J, Biro S, Kono S, Otonari T, Ikeda Y, DDV investigators.
    Hypertens Res; 2010 Sep 21; 33(9):886-91. PubMed ID: 20555331
    [Abstract] [Full Text] [Related]

  • 16. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C, Croce G, Desideri G.
    Adv Ther; 2008 Apr 21; 25(4):300-20. PubMed ID: 18449492
    [Abstract] [Full Text] [Related]

  • 17. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 18. Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine.
    Miyagawa K, Dohi Y, Nakazawa A, Sugiura T, Yamashita S, Sato K, Kimura G.
    Clin Exp Hypertens; 2010 Jan 20; 32(1):1-7. PubMed ID: 20144066
    [Abstract] [Full Text] [Related]

  • 19. Renoprotective efficacy of valsartan in chronic non-diabetic proteinuric nephropathies with renin-angiotensin system gene polymorphisms.
    Lee YJ, Jang HR, Kim SG, Chae DW, Do JY, Lee JE, Huh W, Kim DJ, Oh HY, Kim YG.
    Nephrology (Carlton); 2011 Jul 20; 16(5):502-10. PubMed ID: 21303424
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
    Andrés A, Morales E, Morales JM, Bosch I, Campo C, Ruilope LM, Valsartan in Renal Transplantation Group.
    Transplant Proc; 2006 Oct 20; 38(8):2419-23. PubMed ID: 17097955
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.